Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to April 2010

Designing an Individually Tailored Cancer Treatment Utilizing Advanced CTC Molecular Analysis

April 2010

By Steven Nemeroff, ND

The Battle is Fought at the Cellular Level

The Battle is Fought at the Cellular Level

Chemotherapy drugs can interact with cancer cells in various ways. These crucial interactions can decide the winner in the battle between the cancer and the chemotherapy drug. For example, some chemotherapy drugs only become fully activated after entering the cancer cell. This process is dependent upon the presence of certain enzymes within the cancer cell. A reduced production of these enzymes can lead to poor activation of the chemotherapy agent, resulting in a diminished anti-cancer effect. One chemotherapy drug which requires enzymatic activation is fluorouracil (5-FU), which is converted into its active form within the cancer cell by the enzyme uridine phosphorylase. Studies have shown that cancer cells resistant to 5-FU have a reduced expression of uridine phosphorylase.10,11

Gemzar® is a chemotherapy drug used in the treatment of lung, pancreatic, bladder, and breast cancer. Gemzar® requires the enzyme deoxycytidine kinase (DCK)—manufactured within the cancer cell—to become fully activated. Cancers that produce lesser amounts of DCK are protected from the effects of Gemzar®.12

Chemotherapy drugs can also exert their therapeutic effects by inhibiting essential enzymes within the cancer cell. The overexpression of these enzymes—called drug targets—can enhance the tumor destructive effects of these drugs. Adriamycin® (doxorubicin) is a prime example of this mechanism of action. The main drug target for Adriamycin® is topoisomerase 2. Studies have demonstrated that those patients with cancers expressing higher levels of topoisomerase 2 can benefit from treatment with Adriamycin®.13

Cancer cells also have the ability to produce enzymes that convert chemotherapy drugs into less potent forms, which weakens the anti-tumor activity of these drugs. 5-FU is commonly used in the treatment of breast and colon cancer. Dihydropyrimidine dehydrogenase (DPD) is an enzyme that degrades 5-FU to an inactive metabolite. Cancer cells expressing higher levels of DPD can be resistant to 5-FU. One study of colorectal cancer patients treated with 5-FU revealed that those with high DPD levels had significantly shorter overall survival compared to patients with low DPD expression.14

Cyclophosphamide (Cytoxan®) is utilized in the treatment of lymphoma, leukemia, and cancers of the breast, ovary, and bladder. Cancer cells produce an enzyme called gamma-glutamylcysteine synthetase (GCS), which metabolizes and inactivates cyclophosphamide. Cancer cells that manufacture greater amounts of GCS can possess a tactical advantage in the battle against cyclophosphamide.15

Other genetic expressions within the cancer cell can have a significant impact upon the effectiveness of chemotherapy drugs. The platinum drugs—cisplatin, carboplatin, oxaliplatin—are used in the treatment of ovarian, bladder, testicular, and lung cancer. These drugs inflict damage upon the cancer cell by attacking DNA. Cancer cells produce the excision repair cross-complementation 1 (ERCC1) protein, which is able to repair the damage caused by these drugs. Greater production of ERCC1 offers cancer cells a degree of immunity from platinum drugs.

A team of researchers in Italy measured ERCC1 mRNA levels in lung cancer patients receiving cisplatin.16 The researchers found a dramatic difference in survival based on the levels of ERCC1. Patients with cancers expressing lower levels of ERCC1 had a median overall survival of 23 months, compared to a median overall survival of 12.4 months in those with higher ERCC1 levels.

Methotrexate is a member of the “one size fits all” chemotherapy regimen for breast cancer. Methotrexate wields its tumoricidal activity by blocking an enzyme within the cancer cell called dihydrofolate reductase (DHFR). Cancer cells can compensate by producing more DHFR. Overproduction of DHFR provides cancer cells with a defense against methotrexate.17

In the battle against chemotherapy drugs, some cancers have developed a very clever mechanism to shift the balance of power in their favor. Multidrug resistance 1 (MDR1) is able to conveniently transport chemotherapy drugs out of the cancer cell, which drastically reduces their cancer-killing ability. Cancers that generate greater amounts of MDR1 are resistant to multiple chemotherapy drugs, such as vincristine, Taxol®, mitomycin C, and Adriamycin®.18,19

Advanced CTC Analysis is Now Available

As an added benefit, genetic analysis of CTC can inform us as to which natural supplements might be best indicated. For instance, nuclear factor-kappaB (NF-kB) promotes the growth of cancer. Curcumin is an inhibitor of NF-kB.20 So, a person whose cancer is expressing high levels of NF-kB might consider including curcumin as part of their supplement program.

Some cancers are able to produce glutathione S-transferase pi (GST-pi), which confers resistance to multiple chemotherapy drugs. Ellagic acid—from pomegranate—inhibits GST.21 Supplementation with ellagic acid may be wise if CTC analysis demonstrates overproduction of GST-pi.

Advanced CTC Analysis is Now Available

When taking into consideration the numerous characteristics of the cancer that create its unique genetic fingerprint, we can now fully appreciate the radical differences that can occur between individuals with the “same” cancer, which may require distinctly different treatments. CTC analysis can now allow medical science to take the next step in cancer treatment by uncovering the key distinctions within the cancer—which ultimately distinguishes those with the “same” cancer from one another. The results of CTC analysis can help to ensure the design of a therapy best suited for an individual’s cancer. Fortunately, advanced CTC assays are now available.

CTC analysis can now allow medical science to take the next step in cancer treatment by uncovering the key distinctions within the cancer—which ultimately distinguishes those with the “same” cancer from one another.

For assistance in facilitating the advanced circulating tumor cell (CTC) molecular analysis available at European laboratories, you can contact the International Strategic Cancer Alliance (ISCA) at 610-628-3419.

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.


1. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998 Sep 19;352(9132):930-42.

2. Gelber RD, Cole BF, Goldhirsch A, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet. 1996 Apr 20;347(9008):1066-71.

3. Hayes DF, Thor AD, Dressler LG, et al. Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11;357(15):1496-506.

4. Moore A. Breast-cancer therapy—looking back to the future. N Engl J Med. 2007 Oct 11;357(15):1547-9.

5. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008 Jan 2;100(1):14-20.

6. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1;97(11):2869-79.

7. Kuukasjärvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997 Apr 15;57(8):1597-604.

8. Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8.

9. Wülfing P, Borchard J, Buerger H, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006 Mar 15;12(6):1715-20.

10. Chung YM, Park S, Park JK, et al. Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett. 2000 Oct 16;159(1):95-101.

11. Inaba M, Mitsuhashi J, Sawada H, et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res. 1996 Feb;87(2):212-20.

12. Sebastiani V, Ricci F, Rubio-Viqueira B, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 2006 Apr 15;12(8):2492-7.

13. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002 May;8(5):1107-16

14. Ciaparrone M, Quirino M, Schinzari G, et al. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology. 2006;70(5):366-77.

15. Richardson ME, Siemann DW. Thiol-related mechanisms of resistance in a murine tumor model. Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):387-92.

16. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006 Dec;17(12):1818-25

17. Takemura Y, Kobayashi H, Miyachi H. Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance. Int J Hematol. 1997 Dec;66(4):459-77.

18. Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000 Aug 16;92(16):1295-302.

19. Litman T, Druley TE, Stein WD, et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci. 2001 Jun;58(7):931-59.

20. Siwak DR, Shishodia S, Aggarwal BB, et al. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer. 2005 Aug 15;104(4):879-90.

21. Hayeshi R, Mutingwende I, Mavengere W, et al. The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin. Food Chem Toxicol. 2007 Feb;45(2):286-95.